Core Points - Rosen Law Firm is reminding purchasers of Hims & Hers Health, Inc. common stock of the lead plaintiff deadline for a class action lawsuit, which is August 25, 2025 [1] - Investors who purchased Hims common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] Company Details - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [4] - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which would ensure continued access to Wegovy, and that positive statements were made about the partnership while omitting critical details [4] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [3] - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [3]

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025, and the lead plaintiff deadline is August 25, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2][5] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in representing clients [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4] - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings of compounded semaglutide products [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading information [4]

NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

NEW YORK, July 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Core Viewpoint - PetMed Express, Inc. has received a notice from Nasdaq regarding non-compliance with listing rules due to the late filing of its Annual Report on Form 10-K for the fiscal year ending March 31, 2025 [1][3]. Group 1: Compliance and Filing Status - The notice indicates that the company must submit a plan to regain compliance within 60 days, by September 1, 2025, and may receive an extension of up to 180 days to regain compliance [3]. - The company filed a Notification of Late Filing on Form 12b-25, stating it was unable to file the Form 10-K on time due to ongoing efforts to compile and analyze necessary financial information [3][4]. - The company is working diligently to complete its financial statements and plans to file the Form 10-K as soon as possible to regain compliance with Nasdaq listing rules [4]. Group 2: Company Overview - PetMed Express, Inc. is a pioneer in the direct-to-consumer pet healthcare sector, operating as a national online pharmacy licensed across all 50 states [5]. - The company offers a comprehensive range of pet health solutions, including pharmaceuticals, compounded medications, and OTC supplements, focusing on value, convenience, and care for pet wellness [5].

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases-investigations/hims-hers-health-inc-class-action. Investors have until August 25, 2025, to ask th ...

Core Viewpoint - Hims & Hers Health Inc. is under investigation for potential securities fraud related to misleading statements made to investors during a specified Class Period [1][2]. Group 1: Investigation Details - Berger Montague is investigating whether Hims & Hers violated federal securities laws by making false or misleading statements during the Class Period from April 29, 2025, to June 22, 2025 [1]. - Following the termination of a partnership with Novo Nordisk due to unauthorized marketing and sale of compounded semaglutide drugs, Hims & Hers' shares dropped over 34% on June 23, 2025 [2]. - A complaint has been filed alleging material misstatements and omissions in violation of federal securities laws [2]. Group 2: Legal Action - Investors have until August 25, 2025, to seek appointment as lead plaintiff in the class action lawsuit, which allows them to direct the case and advocate for other harmed investors [3].

Core Insights - Earth Science Tech, Inc. (ETST) has qualified for and been listed on the newly launched OTCID tier of the OTC Markets, reflecting its commitment to enhanced disclosure and compliance standards [1][2] - The CEO, Giorgio R. Saumat, highlighted the company's significant turnaround over the past two years and expressed optimism about future growth and increased investor confidence due to this new designation [3] Company Overview - ETST operates as a strategic holding company focused on acquiring and optimizing high-potential businesses, with current operations in compounding pharmaceuticals, telemedicine, and real estate development through various subsidiaries [4] - The company's subsidiaries include RxCompoundStore.com, Peaks Curative, Avenvi, Mister Meds, and others, each specializing in different aspects of healthcare and real estate [4][10] Subsidiary Highlights - **RxCompoundStore.com**: A fully licensed compounding pharmacy serving multiple states and actively pursuing licensure in remaining U.S. states [5] - **Mister Meds**: A compounding pharmacy in Texas that received full licensure in March 2025 and is expanding its service area [6] - **Peaks Curative**: A telemedicine platform offering consultations for compounded medications and recently expanded into the veterinary market [7] - **Las Villas Health Care**: A healthcare facility focused on the Spanish-speaking community, providing specialized health services [8] - **Avenvi**: A diversified real estate company managing development and financing activities, overseeing a $5 million share repurchase program [10] - **Earth Science Foundation**: A nonprofit organization supporting individuals with financial needs for prescription costs [11]